View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 25, 2020

Coronavirus company news summary – CEPI to sign manufacturing deals for Covid-19 vaccines – Fulcrum to launch Phase III study of losmapimod

By Allie Nawrat

25 June 2020

US-based clinical-stage biopharmaceutical company Fulcrum Therapeutics has secured early notification from the US Food and Drug Administration (FDA) that it may proceed with the initiation of a Phase III, randomised, double-blind, placebo-controlled trial of losmapimod in higher risk adults suffering and hospitalised with Covid-19. Losmapimod is an orally available selective p38α/β mitogen activated protein kinase (MAPK) inhibitor.

Coalition for Epidemic Preparedness Innovation (CEPI) intends to have two to three facilities for manufacturing of each vaccine it is supporting, reported Reuters. It has supported nine potential coronavirus vaccines to date and has identified manufacturing companies with capacity to produce four billion doses annually.

Researchers of Edinburgh University will conduct a trial to find if salt water can help in the treatment of coronavirus. Researchers have begun recruiting people in Scotland showing Covid-19 symptoms or those who are infected with coronavirus. This trial is being funded by Breathe, a data research hub. An earlier study indicated that salt water can help reduce common cold, according to the BBC.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology